[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer

Exclusion Criteria

• •Metastatic disease on standard staging imaging (beyond regional lymph node involvement).
• •o Absence of metastatic disease (beyond regional lymph node involvement) as defined by a negative bone scan, NaF PET, CT chest/abdomen/pelvis, or total body MRI.
• •Prior treatment of the prostate gland for malignant conditions (surgery, cryotherapy, radiotherapy, or photodynamic therapy).
• •Physician prescription of androgen receptor antagonist therapy (examples: bicalutamide, flutamide, or enzalutamide) during time of protocol scans.
• •o Note: ADT consists of chemical castration (i.e. degarelix) to remove endogenous DHT. Androgen receptor antagonists will bind to the androgen receptor and inhibit FDHT from binding.
• •Patients receiving testosterone supplementation .
• •Any contraindication to baseline MRI based on departmental MR questionnaire, or inability to cooperate for an MRI scan.
• •History of allergic reactions attributed to compounds of similar chemical or biologic composition to FDHT.
• •Hepatic laboratory values:
• •1. Bilirubin \>1.5 x ULN (institutional upper limits of normal)
• •2. AST/ALT \>2.5 x ULN
• •3. Albumin \<2 g/dL
• •Creatinine \>2.5 mg/dL
• •Calcium \>11 mg/dL
• •Other serious illness(es) which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.